[go: up one dir, main page]

WO2002102994A3 - Proteines secretees humaines - Google Patents

Proteines secretees humaines Download PDF

Info

Publication number
WO2002102994A3
WO2002102994A3 PCT/US2002/008278 US0208278W WO02102994A3 WO 2002102994 A3 WO2002102994 A3 WO 2002102994A3 US 0208278 W US0208278 W US 0208278W WO 02102994 A3 WO02102994 A3 WO 02102994A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/008278
Other languages
English (en)
Other versions
WO2002102994A2 (fr
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP02760994A priority Critical patent/EP1379132A4/fr
Priority to CA002441832A priority patent/CA2441832A1/fr
Priority to AU2002326293A priority patent/AU2002326293A1/en
Publication of WO2002102994A2 publication Critical patent/WO2002102994A2/fr
Publication of WO2002102994A3 publication Critical patent/WO2002102994A3/fr
Anticipated expiration legal-status Critical
Priority to US11/346,470 priority patent/US20060223088A1/en
Priority to US12/198,817 priority patent/US7968689B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des polypeptides sécrétés humains, ainsi que des molécules d'acides nucléiques isolés codant lesdits polypeptides, servant à diagnostiquer et à traiter des maladies et des affections auto-immunes. L'invention concerne également des anticorps qui fixent ces polypeptides, ainsi que des vecteurs, des cellules hôtes, des méthodes de recombinaison et de synthèse pour produire lesdits polynucléotides, polypeptides et/ou anticorps. L'invention concerne en outre des méthodes de criblage servant à identifier des agonistes et des antagonistes des polynucléotides et polypeptides de l'invention. Elle concerne enfin des méthodes et des compositions servant à inhiber ou stimuler la production et la fonction des polypeptides de l'invention.
PCT/US2002/008278 1997-03-07 2002-03-19 Proteines secretees humaines Ceased WO2002102994A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02760994A EP1379132A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
CA002441832A CA2441832A1 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
AU2002326293A AU2002326293A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
US11/346,470 US20060223088A1 (en) 1997-03-07 2006-02-03 Human secreted proteins
US12/198,817 US7968689B2 (en) 1997-03-07 2008-08-26 Antibodies to HSDEK49 polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/981,876 Continuation-In-Part US7053190B2 (en) 1997-03-07 2001-10-19 Secreted protein HRGDF73
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10472532 A-371-Of-International 2002-03-19
US11/346,470 Continuation-In-Part US20060223088A1 (en) 1997-03-07 2006-02-03 Human secreted proteins

Publications (2)

Publication Number Publication Date
WO2002102994A2 WO2002102994A2 (fr) 2002-12-27
WO2002102994A3 true WO2002102994A3 (fr) 2003-07-24

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/008278 Ceased WO2002102994A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008279 Ceased WO2002090526A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par les humains
PCT/US2002/008276 Ceased WO2002076488A1 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008123 Ceased WO2002102993A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par l'homme
PCT/US2002/009785 Ceased WO2002095010A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008277 Ceased WO2003038063A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
PCT/US2002/008124 Ceased WO2003004622A2 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees

Family Applications After (6)

Application Number Title Priority Date Filing Date
PCT/US2002/008279 Ceased WO2002090526A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par les humains
PCT/US2002/008276 Ceased WO2002076488A1 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees
PCT/US2002/008123 Ceased WO2002102993A2 (fr) 1997-03-07 2002-03-19 Proteines secretees par l'homme
PCT/US2002/009785 Ceased WO2002095010A2 (fr) 1997-03-07 2002-03-19 Proteines secretees humaines
PCT/US2002/008277 Ceased WO2003038063A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
PCT/US2002/008124 Ceased WO2003004622A2 (fr) 1997-03-07 2002-03-19 Proteines humaines secretees

Country Status (4)

Country Link
EP (7) EP1414845A4 (fr)
AU (6) AU2002363296A1 (fr)
CA (7) CA2441755A1 (fr)
WO (7) WO2002102994A2 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9593167B2 (en) 2006-10-27 2017-03-14 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
CA2295474A1 (fr) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 proteines humaines secretees
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
IL139699A0 (en) 1998-06-01 2002-02-10 Urogenesys Inc Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
WO2000042073A1 (fr) 1999-01-15 2000-07-20 Biogen, Inc. Antagonistes de la proteine tweak et du recepteur de tweak, et leur utilisation pour traiter des affections immunitaires
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (fr) * 2000-07-25 2006-11-02 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
AU2002243444A1 (en) 2000-10-31 2002-06-24 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP2280030A3 (fr) 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
US7250495B2 (en) 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (fr) 2001-09-06 2014-12-31 Agensys, Inc. Acide nucléique et protéine corréspondante designés par STEAP-1 utiles dans le traitement et la détection du cancer
WO2003033727A1 (fr) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Procede de criblage d'un inhibiteur de la mort cellulaire
MXPA04009683A (es) 2002-04-09 2005-01-11 Biogen Idec Inc Metodos para el tratamiento de condiciones relacionadas a tweak.
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
WO2005040367A1 (fr) * 2003-10-14 2005-05-06 Baxter International Inc. Polypeptide vkcorc1 de recyclage de la vitamine k-epoxide, cible therapeutique de la coumarine et de ses derives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1794174B1 (fr) * 2004-09-01 2012-06-06 Dynavax Technologies Corporation Procedes et compositions permettant d'inhiber des reponses immunitaires innees et auto-immunite correspondante
CA2579349A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents pour le traitement ou la prevention d'une affection allergique
WO2006026808A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Methode de diagnostic et/ou de prediction du developpement d'une affection allergique
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
DK1853700T3 (da) 2005-02-28 2013-01-07 Baxter Int Rekombinant co-ekspression af vitamin-k-epoxid-reduktase-underenhed 1 til forbedring af vitamin-k-afhængig proteinekspression
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
EP1885388B1 (fr) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US20090054307A1 (en) * 2005-09-01 2009-02-26 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
EP2209896B1 (fr) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Procédés et compositions pour inhiber les réponses immunitaires et l'auto-immunité
CN101932728B (zh) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 脂连蛋白受体片段和使用方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
CA2777698A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afferentes
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
WO2012088222A2 (fr) 2010-12-21 2012-06-28 The University Of North Carolina At Chapel Hill Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3559223A1 (fr) 2016-12-23 2019-10-30 President and Fellows of Harvard College Édition génique de pcsk9
US10450119B2 (en) * 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
CN110709174A (zh) 2017-06-22 2020-01-17 宝洁公司 包括水溶性层和气相沉积有机涂层的膜
PH12022553015A1 (en) 2020-04-09 2024-05-20 Verve Therapeutics Inc Base editing of pcsk9 and methods of using same for treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
JP2002520050A (ja) * 1998-07-15 2002-07-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７１個のヒト分泌タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] SANGER CENTRE, HINXTON, UK; 27 November 2000 (2000-11-27), PEARCE A.: "Human DNA sequence from clone RP11-50D16 on chromosome 13, complete sequence", XP002963946, accession no. EMBL Database accession no. (AL445590) *
See also references of EP1379132A4 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US9593167B2 (en) 2006-10-27 2017-03-14 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8889834B2 (en) 2007-08-23 2014-11-18 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en) 2007-08-23 2014-11-11 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en) 2007-08-23 2015-03-17 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871914B2 (en) 2007-08-23 2014-10-28 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en) 2007-08-23 2016-11-15 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9394568B2 (en) 2014-07-15 2016-07-19 Kymab Limited Methods of treating anaemia
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9187562B1 (en) 2014-07-15 2015-11-17 Kymab Limited Methods for treating anaemia
US9303089B2 (en) 2014-07-15 2016-04-05 Kymab Limited Methods of treating anaemia
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9428578B2 (en) 2014-07-15 2016-08-30 Kymab Limited Methods of treating anaemia
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12129306B2 (en) 2017-04-03 2024-10-29 Hoffman-La Roche Inc. Antibodies binding to STEAP-1

Also Published As

Publication number Publication date
EP1423134A2 (fr) 2004-06-02
AU2002320013A1 (en) 2002-11-18
WO2002102994A2 (fr) 2002-12-27
EP1379132A4 (fr) 2009-07-01
AU2002354719A1 (en) 2003-01-21
EP1379264A4 (fr) 2009-07-08
EP1414845A2 (fr) 2004-05-06
WO2003038063A2 (fr) 2003-05-08
CA2441702A1 (fr) 2002-12-27
EP1404702A2 (fr) 2004-04-07
CA2441840A1 (fr) 2002-11-28
WO2003004622A2 (fr) 2003-01-16
WO2002095010A3 (fr) 2004-02-12
AU2002324424A1 (en) 2002-12-03
EP1381622A2 (fr) 2004-01-21
AU2002326293A1 (en) 2003-01-02
EP1379264A1 (fr) 2004-01-14
AU2002332391A1 (en) 2003-01-02
CA2441755A1 (fr) 2003-05-08
EP1390390A4 (fr) 2009-07-08
WO2003038063A3 (fr) 2003-12-11
WO2002090526A2 (fr) 2002-11-14
WO2002095010A2 (fr) 2002-11-28
AU2002363296A1 (en) 2003-05-12
EP1414845A4 (fr) 2009-07-08
WO2002102993A3 (fr) 2004-03-25
WO2003004622A3 (fr) 2004-02-19
CA2441417A1 (fr) 2002-11-14
EP1390390A2 (fr) 2004-02-25
WO2002090526A3 (fr) 2003-10-30
WO2002102993A2 (fr) 2002-12-27
CA2441832A1 (fr) 2002-12-27
CA2441397A1 (fr) 2002-10-03
WO2002076488A1 (fr) 2002-10-03
EP1379132A2 (fr) 2004-01-14
EP1404702A4 (fr) 2009-07-08
CA2441416A1 (fr) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2002102994A3 (fr) Proteines secretees humaines
WO2002077186A3 (fr) Proteines secretees par l'etre humain
WO2001055310A8 (fr) Acides nucleiques, proteines et anticorps
WO2001054472A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055306A3 (fr) Acides nucleiques, proteines, et anticorps
WO2001055326A3 (fr) Acides nucleiques, proteines et anticorps
WO2004042000A3 (fr) 157 proteines secretees humaines
WO2001055168A8 (fr) Acides nucleiques, proteines, et anticorps
WO2002072763A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055162A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055305A3 (fr) Acides nucleiques, proteines, et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441832

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002760994

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002760994

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP